Worcester-based biopharmaceutical startup Nemucore Medical Innovations said it has closed its Series A financing round to fund the advance of its clinical-stage ovarian cancer therapy, among other activities.
The therapy, called NMI-900, will proceed to a phase 2b trial in ovarian cancer. Meanwhile, the funding will also help expand Nemucore’s oncology pipeline and support general corporate purposes, according to a statement. Financial terms were not disclosed.
Nemucore President and CEO Timothy P. Coleman said in a statement that the Series A round “recognizes the capital efficiency of our organization, as we have successfully advanced novel therapies for difficult-to-treat cancers.”
